EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieValidierungsstudieOpen Access · CC BY 4.0

Refining the Multivariable Predictive‐Prognostic PREDICTR ‐ OPC Model for Survival in Surgical Escalation for Oropharyngeal Squamous Cell Carcinoma

Lauren L Zhang iD, Caroline Kristunas, C Max Robinson, Jill M Brooks, Alice J Sitch, Stuart C Winter, Justin Weir, Paul Matthews, Terry M Jones, Keith Hunter, Pawel Golusinski, Ketan A Shah und 7 weitere

The Laryngoscope · 2026

DOI: 10.1002/lary.70611 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Laryngoscope, 2026. Verfasst von Lauren L Zhang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Oropharyngeal Neoplasms. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The PREDICTR‐OPC model is the only prognostic classifier for oropharyngeal squamous cell carcinoma (OPSCC) also predictive of surgical outcomes. Of the four biomarkers included, survivin contributes minimally and presents practical limitations. This study aimed to refine and simplify the model by removing survivin, then re‐assess its prognostic predictive performance compared to the original.

Methods

This retrospective cohort study analyzed a multi‐center training cohort ( n = 600) and an external validation cohort ( n = 385) of OPSCC patients. Tumor biopsies were stained for p16, high‐risk human papillomavirus (HR‐HPV) DNA, tumor‐infiltrating lymphocytes (TILs), and survivin and independently scored by at least three certified pathologists. Cox proportional hazards models assessed overall survival (OS), comparing three‐biomarker (p16, HR‐HPV, TILs) and four‐biomarker models. Hazard ratios (HRs) for OS were estimated in the validation cohort, adjusting for covariates. Discrimination, calibration, and decision curve analysis (DCA) evaluated performance and clinical utility.

Results

Among 985 patients (median age: 57 years), median OS = 8.8 years (95% CI: 6.9–10.5). The three‐biomarker model yielded HR = 4.10 (95% CI: 2.41–6.98, p < 0.001) for high‐ vs. low‐risk groups in the validation cohort, comparable to the four‐biomarker model (HR = 4.24, p < 0.001). Surgery was associated with improved OS in high‐risk (HR = 0.45, p = 0.001) but not low‐risk (HR = 0.83, p = 0.72) patients, consistent with the original model. The models performed similarly across all metrics (e.g., Concordance Index: 0.71 vs. 0.72; Brier Score: 0.22 for both) as was model fit (Likelihood Ratio Test: p = 0.066). DCA revealed comparable clinical benefit.

Conclusion

Removing survivin preserves PREDICTR‐OPC's predictive performance, offering a more cost‐effective, easier‐to‐implement tool for OPSCC treatment recommendations. Level of Evidence 3

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Squamous CellOropharyngeal NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedBiomarkers, TumorPredictive Value of TestsPrognosisProportional Hazards ModelsRetrospective StudiesSurvivin

Stichwörter der Autor:innen

human papillomavirusoropharyngeal squamous cell carcinomaprognostic modelsurgical escalation

Substanzen

Biomarkers, TumorSurvivin

Autor:innen und Institutionen

  • Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
  • Department of Cancer and Genomic Sciences, University of Birmingham, Institute of Head and Neck Studies and Education (InHANSE), Birmingham, UK.
  • Department of Cellular Pathology, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK.
  • Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
  • NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.

ORCID-Profile: Lauren L Zhang

Förderung

  • Cancer Research UK

Zitieren

APA

Zhang, L. L., Kristunas, C., Robinson, C. M., Brooks, J. M., Sitch, A. J., Winter, S. C., Weir, J., Matthews, P., Jones, T. M., Hunter, K., Golusinski, P., Shah, K. A., Thavaraj, S., West, C. M., Haider, S., Odell, E., Nankivell, P., von Zeidler, S. V., & Mehanna, H. (2026). Refining the Multivariable Predictive‐Prognostic PREDICTR ‐ OPC Model for Survival in Surgical Escalation for Oropharyngeal Squamous Cell Carcinoma. The Laryngoscope. https://doi.org/10.1002/lary.70611

Vancouver

Zhang LL, Kristunas C, Robinson CM, Brooks JM, Sitch AJ, Winter SC, et al. Refining the Multivariable Predictive‐Prognostic PREDICTR ‐ OPC Model for Survival in Surgical Escalation for Oropharyngeal Squamous Cell Carcinoma. The Laryngoscope. 2026. doi:10.1002/lary.70611

BibTeX
@article{Zhang2026,
  author = {Zhang, Lauren L and Kristunas, Caroline and Robinson, C Max and Brooks, Jill M and Sitch, Alice J and Winter, Stuart C and Weir, Justin and Matthews, Paul and Jones, Terry M and Hunter, Keith and Golusinski, Pawel and Shah, Ketan A and Thavaraj, Selvam and West, Catharine M and Haider, Syed and Odell, Edward and Nankivell, Paul and von Zeidler, Sandra V and Mehanna, Hisham},
  title = {Refining the Multivariable Predictive‐Prognostic PREDICTR ‐ OPC Model for Survival in Surgical Escalation for Oropharyngeal Squamous Cell Carcinoma},
  journal = {The Laryngoscope},
  year = {2026},
  doi = {10.1002/lary.70611}
}
Kostenlos starten →